Basal serum levels of FSH and estradiol in ovulatory and anovulatory women undergoing treatment by in-vitro maturation of immature oocytes
- PMID: 12151427
- DOI: 10.1093/humrep/17.8.1997
Basal serum levels of FSH and estradiol in ovulatory and anovulatory women undergoing treatment by in-vitro maturation of immature oocytes
Abstract
Background: The study aim was to establish whether basal serum levels of FSH and estradiol are predictive of outcome in women undergoing treatment by in-vitro maturation (IVM) of immature oocytes.
Methods: Data were obtained from 123 unstimulated IVM cycles. Serum was taken between cycle days 2-4 for analysis. Patients received 10 000 IU of HCG 36 h before immature oocyte recovery that was performed between cycle days 9-14. IVM was performed and mature oocytes fertilized by ICSI, followed 2-3 days later by embryo transfer. Outcome measures included the number of immature oocytes retrieved, and the rates of oocyte maturation, fertilization, cleavage and pregnancy.
Results: A median (range) of 8 (0-36) immature oocytes was retrieved per patient. Oocyte maturation, fertilization, cleavage and pregnancy rates were 83, 76, 93 and 17.9% respectively. Serum FSH levels and the presence of polycystic ovary were significant independent predictors of the number of immature oocytes retrieved, whilst patient age and basal estradiol level were not. A basal serum estradiol level >100 pmol/l was associated with a significantly higher pregnancy rate (26 versus 11% for estradiol <100 pmol/l; P = 0.032).
Conclusions: Measurement of basal serum levels of FSH and estradiol are useful in predicting the number of immature oocytes retrieved and the pregnancy rate in women undergoing unstimulated IVM treatment.
Similar articles
-
Exposure to human chorionic gonadotropin during in vitro maturation does not improve the maturation rate and developmental potential of immature oocytes from patients with polycystic ovary syndrome.Fertil Steril. 2008 Jan;89(1):98-103. doi: 10.1016/j.fertnstert.2007.02.021. Epub 2007 May 24. Fertil Steril. 2008. PMID: 17524398 Clinical Trial.
-
[In vitro maturation and fertilization of unstimulated immature oocyte for the treatment of infertile women].Zhonghua Fu Chan Ke Za Zhi. 2006 Mar;41(3):173-6. Zhonghua Fu Chan Ke Za Zhi. 2006. PMID: 16640883 Chinese.
-
Possible factors affecting the development of oocytes in in-vitro maturation.Hum Reprod. 2000 Dec;15 Suppl 5:11-7. doi: 10.1093/humrep/15.suppl_5.11. Hum Reprod. 2000. PMID: 11263532 Clinical Trial.
-
State of the art in in-vitro oocyte maturation.Curr Opin Obstet Gynecol. 2004 Jun;16(3):211-9. doi: 10.1097/00001703-200406000-00003. Curr Opin Obstet Gynecol. 2004. PMID: 15129050 Review.
-
In-vitro maturation of oocytes from unstimulated polycystic ovaries.Reprod Biomed Online. 2002;4 Suppl 1:18-23. doi: 10.1016/s1472-6483(12)60007-8. Reprod Biomed Online. 2002. PMID: 12470331 Review.
Cited by
-
The effect of immature oocytes quantity on the rates of oocytes maturity and morphology, fertilization, and embryo development in ICSI cycles.J Assist Reprod Genet. 2012 Aug;29(8):803-10. doi: 10.1007/s10815-012-9799-6. Epub 2012 May 30. J Assist Reprod Genet. 2012. PMID: 22644633 Free PMC article.
-
Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment.J Assist Reprod Genet. 2011 Jun;28(6):501-8. doi: 10.1007/s10815-011-9589-6. Epub 2011 Jun 15. J Assist Reprod Genet. 2011. PMID: 21671163 Free PMC article.
-
Application of serum anti-Müllerian hormone levels in selecting patients with polycystic ovary syndrome for in vitro maturation treatment.Clin Exp Reprod Med. 2016 Jun;43(2):126-32. doi: 10.5653/cerm.2016.43.2.126. Epub 2016 Jun 23. Clin Exp Reprod Med. 2016. PMID: 27358832 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources